NCT07506616

Membrane Potential Mapping with18F-TPP

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 21 Years – 80 Years
• Healthy volunteers: Accepted

Summary

In this study, investigators propose to use PET imaging to study the pharmacokinetics of 18F-TPP and develop methods for imaging membrane potential (ΔΨT) in humans.

Detailed description

The aims of this study are: 1. Assessment of the pharmacokinetics of primed constant infusion of 18F-TPP in humans. 2. Assessment of normal variation of membrane potential (ΔΨT) and extracellular space (ECS) in a cohort of "normal" subjects. 3. Assessment of the pharmacokinetics of bolus injection of 18F-TPP in humans. Studies will be performed on a PET/CT scanner. A separate MRI will be collected. Each scan may or may not have arterial blood sampling for measurement of the time course of radioactivity in the whole-blood, plasma and radiometabolite analysis on selected plasma samples.

Conditions

• Membrane Potential Mapping

Interventions

Type	Name	Description
DRUG	18F-TPP	radiotracer specific for imaging mitochondrial membrane potential (ΔΨm) administered intravenously

Timeline

• Start date: 2026-04-16
• Primary completion: 2033-08-01
• Completion: 2033-08-01
• First posted: 2026-04-01
• Last updated: 2026-04-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study